IHC - ALK 1

IHC – ALK-1 Test

The IHC ALK-1 Test is an advanced immunohistochemistry (IHC) diagnostic test used to detect the presence of Anaplastic Lymphoma Kinase (ALK) protein expression in tissue samples. This test is highly valuable for diagnosing and classifying specific cancers, especially non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors, and certain rare cancers.

ALK is a protein produced by the ALK gene, which can become abnormally activated due to genetic rearrangements or mutations. When this happens, it may lead to uncontrolled tumor cell growth. Detecting ALK protein expression is essential for identifying cancers that may respond to targeted ALK inhibitor therapies, improving treatment precision and outcomes.

The test is usually performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using highly specific antibody staining techniques. Expert pathologists evaluate stained tissue under a microscope to identify ALK protein positivity and assess tumor characteristics.

ALK-1 testing plays a crucial role in precision oncology, helping oncologists select personalized treatment plans and determine eligibility for targeted therapy.

Benefits of the Test

• Detects ALK protein expression accurately
• Supports cancer classification
• Helps identify candidates for targeted therapy
• Assists treatment planning
• Improves diagnostic confidence
• Supports personalized cancer care

Why Doctors Recommend This Test

Doctors commonly recommend the ALK-1 IHC Test when:

• Non-small cell lung cancer is suspected
• ALCL diagnosis requires confirmation
• Tumor molecular classification is needed
• Targeted therapy eligibility assessment is required
• Histopathology suggests ALK-related cancer
• Rare tumor diagnosis requires clarification
• Cancer subtype differentiation is necessary
• Personalized oncology treatment planning is essential

This test ensures evidence-based treatment decisions for better clinical outcomes.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous histopathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the ALK-1 IHC Test is usually 4–7 working days, depending on tissue staining and interpretation complexity.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected NSCLC
• Individuals undergoing lymphoma evaluation
• Patients requiring targeted therapy assessment
• Individuals with unclear tumor classification
• Oncology patients under specialist care
• Patients requiring advanced molecular pathology confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate ALK-1 IHC reports for reliable diagnosis and personalized cancer treatment planning.